Resilience

Resilience is a private, revenue-generating CDMO that has rapidly scaled since its 2020 founding to become a significant North American player in the manufacturing of advanced therapies. The company differentiates itself through a network of integrated facilities, proprietary technology platforms like DAR-T™ for cell therapy, and a strong focus on quality and regulatory success, as evidenced by a 100% pass rate on key inspections. Backed by substantial long-term financing and strategic partnerships, Resilience is positioned to capitalize on the growing outsourcing demand in the biologics and cell/gene therapy sectors.

A biomanufacturing network enhanced by proprietary platforms including Sprout Solutions™ for development, Auto-T™ for automated cell therapy, and DAR-T™ for accelerated and potent CAR-T manufacturing.

Resilience competes in a crowded and competitive CDMO landscape, facing off against large, established players like Lonza, Catalent, and Thermo Fisher Scientific, as well as other specialized advanced therapy CDMOs. Its differentiation is based on its North American network, focus on the most complex modalities, and investment in proprietary manufacturing technologies like DAR-T™.